vTv Therapeutics Inc (NASDAQ:VTVT) major shareholder Ronald O. Perelman acquired 1,358,698 shares of the firm’s stock in a transaction that occurred on Wednesday, May 15th. The shares were purchased at an average price of $1.84 per share, with a total value of $2,500,004.32. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Large shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.
NASDAQ:VTVT opened at $1.59 on Friday. The stock has a market cap of $83.03 million, a P/E ratio of -2.30 and a beta of -3.79. vTv Therapeutics Inc has a 52-week low of $0.68 and a 52-week high of $6.09.
vTv Therapeutics (NASDAQ:VTVT) last posted its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter. The company had revenue of $0.92 million during the quarter. On average, analysts anticipate that vTv Therapeutics Inc will post -0.59 EPS for the current year.
Large investors have recently bought and sold shares of the stock. Wedbush Securities Inc. bought a new position in vTv Therapeutics in the first quarter valued at approximately $30,000. Barclays PLC grew its stake in vTv Therapeutics by 366.7% in the fourth quarter. Barclays PLC now owns 28,000 shares of the biotechnology company’s stock valued at $74,000 after purchasing an additional 22,000 shares in the last quarter. Morgan Stanley grew its stake in vTv Therapeutics by 147,061.5% in the first quarter. Morgan Stanley now owns 19,131 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 19,118 shares in the last quarter. Sabby Management LLC bought a new position in vTv Therapeutics in the first quarter valued at approximately $382,000. Finally, D. E. Shaw & Co. Inc. bought a new position in vTv Therapeutics in the fourth quarter valued at approximately $186,000. Institutional investors and hedge funds own 1.16% of the company’s stock.
TRADEMARK VIOLATION WARNING: “vTv Therapeutics Inc (VTVT) Major Shareholder Purchases $2,500,004.32 in Stock” was published by WKRB News and is the property of of WKRB News. If you are reading this piece of content on another domain, it was illegally copied and republished in violation of international copyright & trademark law. The legal version of this piece of content can be read at https://www.wkrb13.com/2019/05/19/vtv-therapeutics-inc-vtvt-major-shareholder-purchases-2500004-32-in-stock.html.
About vTv Therapeutics
vTv Therapeutics Inc, a clinical-stage biopharmaceutical company, discovers and develops orally administered small molecule drug candidates to fill unmet medical needs. The company is developing Azeliragon, an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts, which is in Phase II/III clinical trials for the treatment of mild Alzheimer's disease.
Recommended Story: What is Call Option Volume?
Receive News & Ratings for vTv Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.